Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28671676 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9ACYP2D6CA12 | |
| SCHEMBL4957038 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9ACYP2D6CA12 | |
| Hydrochloric Acid SCHEMBL7307224 | 0.98 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9ACYP2D6CA12 | |
| SCHEMBL14355566 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ACYP2D6CA12 | |
| Hydrochloric Acid SCHEMBL6044177 | 0.84 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1RAB9ACYP2D6CA12 | |
| Hydrochloric Acid SCHEMBL8684138 | 0.84 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1RAB9ACYP2D6CA12 | |
| SCHEMBL9684035 | 0.82 | L3MBTL1 (0.39) | CA12CA2CA9KDM4EHTT | |
| SCHEMBL28682071 | 0.82 | L3MBTL1 (0.42) | CA12CA2CA9KDM4ELIPE | |
| SCHEMBL8869669 | 0.82 | L3MBTL1 (0.42) | CA12CA2CA9KDM4ELIPE | |
| SCHEMBL12260227 | 0.80 | DPP4 (0.41) | SMN1; SMN2NPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323448-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7148198-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2006-12-12 | — | — | US | disclosed |
| US-20060276409-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2006-12-07 | — | — | US | disclosed |
| US-20050014702-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2005-01-20 | — | — | US | disclosed |
| US-6787522-B2 | BACTERIAL POLYPEPTIDE DEFORMYLASE (PDF) INHIBITORS, N-FORMYL HYDROXYLAMINE DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2004-09-07 | — | — | US | disclosed |
| EP-1052984-B1 | ANTIBACTERIAL AGENTS | VERNALIS OXFORD LTD (GB) | 2004-05-12 | — | — | EP | disclosed |
| US-20020165167-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2002-11-07 | — | — | US | disclosed |
| US-6423690-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2002-07-23 | — | — | US | disclosed |
| EP-1052984-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999039704-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276409-A1 | Antibacterial agents | CBR3, CBR1, SIGMAR1 | SMN1; SMN2 3090/4885NPC1 1406/4885RAB9A 1082/4885 |
| US-20050014702-A1 | Antibacterial agents | CBR3, CBR1, SIGMAR1 | SMN1; SMN2 3090/4885NPC1 1406/4885RAB9A 1082/4885 |
| US-20020165167-A1 | Antibacterial agents | CBR1, CBR3, SIGMAR1 | SMN1; SMN2 3034/4885NPC1 1086/4885RAB9A 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.